Avigen Inc (NASDAQ:AVGN)

Posts Tagged ‘Avigen Inc (NASDAQ:AVGN)’

Catalyst Investment Research on AVGN

Posted in Activist Investors, Avigen (NASDAQ:AVGN), Biotechnology Value Fund, Net Cash Stocks, tagged Activist investment, Avigen Inc (NASDAQ:AVGN), Biotechnology Value Fund, Liquidating Value, Net Cash Stock on March 25, 2009 | Leave a Comment »

Hedge Fund Solutions, which produces The Official Activist Investing Blog, recently announced the launch of a new investment research product, Catalyst Investment Research, which is “dedicated to uncovering undervalued publicly traded companies that could have the potential to generate outsized returns due to an activist investor’s involvement.” Sounds like a good idea to us. Catalyst [...]

Read Full Post »

AVGN to explore settlement with BVF

Posted in Activist Investors, Avigen (NASDAQ:AVGN), Biotechnology Value Fund, Net Cash Stocks, Stocks, tagged Activist investment, Avigen Inc (NASDAQ:AVGN), Biotechnology Value Fund, Liquidating Value, Net Cash Stock on March 24, 2009 | Leave a Comment »

Avigen Inc (NASDAQ:AVGN) has authorized its CEO, Dr. Chahine, and RBC to contact Biotechnology Value Fund (BVF) to explore the possibility of negotiating a settlement between BVF and AVGN with respect to BVF’s increased $1.20 per share offer for AVGN. AVGN shareholders are to decide on BVF’s proposal to remove the board of AVGN and [...]

Read Full Post »

Proxy Governance recommends AVGN shareholders support BVF

Posted in Activist Investors, Avigen (NASDAQ:AVGN), Biotechnology Value Fund, Stocks, tagged Activist investment, Avigen Inc (NASDAQ:AVGN), Biotechnology Value Fund, Liquidating Value, Net Cash Stock on March 24, 2009 | Leave a Comment »

Proxy Governance, a proxy advisory firm, has recommended that Avigen Inc (NASDAQ:AVGN) shareholders vote to remove the board of AVGN and elect Biotechnology Value Fund’s (BVF) slate of director nominees at the special meeting of stockholders to be held on March 27, 2009. We’ve been following AVGN (see archived posts here) because it’s a net [...]

Read Full Post »

AVGN files analysis of MNOV offer

Avigen Inc (NASDAQ:AVGN) has filed its assessment of the cash portion of the MediciNova Inc (NASDAQ:MNOV) proposal. We’ve been following AVGN (see archived posts here) because it’s a net cash stock (i.e. it’s trading at less than the value of its cash after deducting all liabilities) and specialist biotechnology investor BVF has been pushing it [...]

Read Full Post »

BVF increases tender offer for AVGN to $1.20 per share

Biotechnology Value Fund (BVF) has increased its tender offer for Avigen Inc (NASDAQ:AVGN) from $1.00 per share to $1.20 per share contingent on the election of BVF’s nominees to the board of AVGN. We’ve been following AVGN (see archived posts here) because it’s a net cash stock (i.e. it’s trading at less than the value [...]

Read Full Post »

Empirical Search Strategies supports Biotechnology Value Fund

Wes Gray’s Empirical Search Strategies (ESS) has proclaimed its support for a “downside protection” measure described by the Biotechnology Value Fund (BVF) in the Avigen Inc (NASDAQ:AVGN) proxy fight. ESS is the beneficial owner of approximately 2.3% of AVGN’s outstanding common stock. We’ve been following AVGN (see archived posts here) because it’s a net cash [...]

Read Full Post »

Here, sir, the people govern?

We cast our proxy votes on-line today in support of Biotechnology Value Fund’s (BVF) proposal to remove the board of Avigen Inc (NASDAQ:AVGN). We’ve been following AVGN (see archived posts here) because it’s a net cash stock (i.e. it’s trading at less than the value of its cash after deducting all liabilities) and specialist biotechnology [...]

Read Full Post »

Glass Lewis say reject BVF proposal; Greenbackd says support BVF proposal

Avigen Inc (NASDAQ:AVGN) has sent a letter sent to its stockholders saying that Glass Lewis, a “leading independent voting advisory service” has reviewed the Biotechnology Value Fund (BVF) proposal to remove AVGN’s board and has recommended that stockholders vote against the proposal. Glass Lewis make the recommendation on the basis that “…shareholders would be best [...]

Read Full Post »

AVGN files letters to MediciNova Inc (NASDAQ:MNOV)

Posted in Activist Investors, Avigen (NASDAQ:AVGN), Biotechnology Value Fund, Stocks, tagged Activist investment, Avigen Inc (NASDAQ:AVGN), Biotechnology Value Fund on March 17, 2009 | Leave a Comment »

Avigen Inc (NASDAQ:AVGN) has filed two letters sent to MediciNova Inc (NASDAQ:MNOV) and intends to present the letters at the special meeting “to demonstrate the tone and character of the negotiation discussions between MediciNova and Avigen and its advisors.” We’ve been following AVGN (see archived posts here) because it’s a net cash stock (i.e. it’s trading [...]

Read Full Post »